NS9775 is compound that is both a monoamine reuptake inhibitor (MRI) and a7 nicotinic #acetylcholinereceptor (nAChR) agonist. MRIs are typically used in the treatment of depression or #ADHD due to their ability to increase the availability of #monoamine#neurotransmitters. MRIs promote increased levels of #serotonin, #norepinephrine, and #dopamine. nAChR agonists promote cognitive function and facilitate monoamine release. MRIs and nAChR agonist have been shown to work in synergy against depression.
Though there is a lack of any human data, clinical or anecdotal; there have been behavioral effects shown in mice studies.
Mice displayed reversed scopolamine-induced deficits, increased forced swim distance, reduced digging in marble burying paradigm, and increased number of punished plate crossings.
This is a very interesting compound that displays pro-cognitive, #antidepressant, and #anxiolytic effects. It is surprising that it has not surfaced in #nootropic or #researchchemical communities yet.